Congenital Zika Syndrome (Zika Virus)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
Congenital Zika syndrome is a pattern of brain, eye and other developmental problems caused by Zika virus infection before birth. The virus can damage the developing brain, leading to a small head, seizures, movement or feeding problems, and impaired vision. Severity varies: not every exposed baby becomes infected or develops the syndrome, and some problems emerge after birth. Follow-up and early developmental support are important even when initial findings are subtle.
Clinical Definition
Congenital Zika syndrome (CZS) results from fetal infection with Zika virus, a flavivirus spread mainly by Aedes mosquitoes and also sexually. Neural precursor injury disrupts brain growth. High-yield findings are severe microcephaly with partial skull collapse, thin cortex with cortical-subcortical junction calcifications, macular scarring/retinal pigment mottling, congenital contractures and marked hypertonia. The spectrum is variable; normal head circumference at birth does not exclude congenital infection or other manifestations. Interpret phenotype, exposure and infant testing together while evaluating other congenital infections and genetic causes.
Inciting Event
Maternal Zika infection during pregnancy, often from an Aedes bite, can lead to fetal infection; transmission and fetal injury are not inevitable.
Sexual transmission of Zika virus from an infected partner to a pregnant woman can also trigger fetal infection.
Maternal viremia allows transplacental passage of the virus to the developing fetus.
Intrauterine infection during critical periods of neurodevelopment leads to congenital abnormalities.
Latency Period
Symptoms and congenital abnormalities typically manifest at birth or are detected on prenatal ultrasound in the second or third trimester.
There is a variable latency from maternal infection to fetal brain damage, often weeks to months.
Microcephaly and other brain abnormalities may be identified during routine mid-pregnancy ultrasound screening.
Some neurological deficits may become apparent only after birth during early infancy.
Diagnostic Delay
Asymptomatic maternal infection often leads to missed or delayed diagnosis of fetal involvement.
Overlap of clinical features with other congenital infections can cause diagnostic confusion.
Limited access to Zika virus PCR and serologic testing in endemic regions delays confirmation.
Prenatal ultrasounds may not detect subtle brain abnormalities early in gestation.
Lack of awareness about Congenital Zika Syndrome in non-endemic areas contributes to delayed recognition.
Clinical Presentation
Signs & Symptoms
Severe microcephaly present at birth or developing postnatally
Seizures due to cortical malformations and brain injury
Feeding difficulties and poor suck reflex
Irritability and hyperexcitability reflecting central nervous system involvement
Visual impairment from retinal and optic nerve abnormalities
History of Present Illness
Pregnant women may report recent febrile illness with rash, conjunctivitis, and arthralgia consistent with Zika virus infection.
Review prenatal imaging for brain growth, cortical abnormalities, calcifications and ventriculomegaly; a normal early scan does not exclude later findings.
Assess for microcephaly, abnormal tone, irritability and seizures, recognizing that not every infected infant has this severe presentation.
Additional findings include ocular abnormalities, hearing loss, and arthrogryposis.
Track head growth and developmental milestones over time; later recognition of deficits does not by itself establish ongoing viral replication.
Past Medical History
Maternal history of recent travel to or residence in Zika-endemic regions is critical.
Previous infections with other flaviviruses such as dengue may be noted but do not prevent Zika infection.
There is no licensed Zika vaccine or established drug prophylaxis; absence of Zika immunization is not a patient-specific risk factor.
No specific maternal chronic illnesses are directly linked to increased risk of congenital Zika syndrome.
History of prior adverse pregnancy outcomes may be relevant but is not specific.
Family History
There is no known heritable genetic predisposition to congenital Zika syndrome.
Family history is typically negative for similar congenital malformations unless due to other causes.
Genetic disorders can mimic congenital infection, including microcephaly and intracranial calcifications. Similar family findings warrant clinical-genetics evaluation.
CZS is not inherited in a Mendelian pattern. A resolved infection before a future pregnancy is not itself expected to cause CZS in that pregnancy; assess timing and any new exposure.
Counsel about infection/exposure timing and consider genetic evaluation when the phenotype or family history suggests an alternative diagnosis.
Physical Exam Findings
Measure occipitofrontal circumference on sex- and gestational-age-appropriate charts; microcephaly is generally below −2 SD and severe microcephaly below −3 SD.
Craniofacial disproportion including prominent occiput and overlapping sutures
Hypertonia and increased muscle tone with spasticity
Arthrogryposis characterized by joint contractures and limited range of motion
Ocular abnormalities such as macular scarring and pigmentary retinal mottling
Diagnostic Workup
Diagnostic Criteria
Suspect CZS from compatible brain/eye or neurologic findings plus possible prenatal exposure, while evaluating alternative causes. Microcephaly is not mandatory. Obtain infant testing promptly: serum and urine NAAT, plus serum IgM. A positive infant NAAT supports confirmed infection; isolated IgM needs cautious interpretation and selected neutralization testing. Maternal infection alone does not confirm fetal infection. Negative tests do not always exclude infection, especially with delayed sampling. Public-health surveillance definitions are distinct from bedside diagnosis.
Pathophysiology
Key Mechanisms
Vertical transmission of Zika virus leads to direct infection of neural progenitor cells, causing impaired neurogenesis and microcephaly.
Experimental neural-precursor studies show increased apoptosis and dysregulated cell-cycle progression, reducing the pool of cells available for brain development.
Infection triggers neuroinflammation and gliosis, contributing to brain tissue damage and calcifications.
Disruption of cortical development results in lissencephaly, ventriculomegaly, and other structural brain abnormalities.
Placental infection can involve Hofbauer cells, the fetal macrophages in chorionic villi. Placental injury is variable; universal oxygen/nutrient failure is not the established explanation for every case.
| Involvement | Details |
|---|---|
| Organs | Brain is the primary organ affected, with microcephaly, ventriculomegaly, and cortical malformations as hallmark features. |
Eyes and visual pathways may be affected: retinal/chorioretinal lesions, optic nerve hypoplasia or atrophy, and cortical visual impairment. | |
Musculoskeletal system shows arthrogryposis due to fetal akinesia from central nervous system damage. | |
| Tissues | Cerebral cortex tissue is severely affected, showing calcifications, cortical thinning, and disrupted architecture. |
Placental tissue serves as a reservoir and transmission route for Zika virus from mother to fetus. | |
Ocular tissue can be damaged, leading to chorioretinal atrophy and visual impairment. | |
| Cells | Neural progenitor cells are targeted by the Zika virus, leading to impaired neurogenesis and microcephaly. |
Microglia and other glial cells participate in antiviral and inflammatory responses; experimental studies suggest roles in viral spread and neural injury. | |
Astrocytes can be infected and produce innate immune responses in experimental systems. These findings do not establish one universal blood-brain-barrier mechanism in every affected fetus. | |
| Chemical Mediators | Type I interferons are critical antiviral cytokines involved in the host immune response to Zika virus infection. |
Inflammatory cytokines and chemokines are induced in experimental infection. Their effects depend on cell type and model; no individual cytokine level diagnoses CZS or predicts its severity. | |
Viral RNA acts as a pathogen-associated molecular pattern triggering innate immune activation in neural tissues. |
Treatments
Pharmacological Treatments
No disease-specific pharmacological treatment is listed for this topic.
Non-pharmacological Treatments
Provide comprehensive supportive care including physical, occupational, and speech therapy to address neurodevelopmental delays.
Assess swallowing safety, aspiration and growth; provide feeding therapy and individualized nutritional support when needed.
Implement early intervention programs to optimize developmental outcomes and manage neurological impairments.
Evaluate suspected seizures with neurology and EEG when indicated; use antiseizure treatment for the clinical syndrome, not routine prophylaxis for all exposed infants.
Coordinate developmental, neurologic, eye and hearing care. Infants with CZS findings generally need head ultrasound and ophthalmologic assessment by one month, plus ABR-based hearing screening and ongoing follow-up.
Prevention
Pharmacological Prevention
No approved antiviral medications or vaccines currently exist for Zika virus prevention
Supportive and developmental care treat consequences of infection; they are not prophylaxis against fetal infection.
Experimental vaccine candidates are under development but not yet available
Acetaminophen may relieve acute fever/discomfort; it does not prevent transmission, fetal infection or CZS.
In suspected acute Zika illness, avoid aspirin/NSAIDs until dengue is excluded because of bleeding risk; this is a treatment precaution, not Zika prophylaxis.
Non-pharmacological Prevention
Use EPA-registered repellents as directed, covering clothing and screens; prevent bites during the day as well as at night.
Elimination of standing water to reduce Aedes mosquito breeding sites
Prevent sexual transmission with condoms or abstinence. When a partner has relevant Zika exposure, use these measures throughout pregnancy; preconception timing also depends on the exposed partner and exposure date.
Check current CDC destination risk and travel notices before travel during pregnancy; avoid destinations with an active Zika notice and discuss other current/past-transmission areas with a clinician.
Testing and ultrasound detect or monitor, rather than prevent, fetal injury. Maternal testing is risk-based; routine testing of every asymptomatic traveler to a past-transmission area is not recommended.
Outcome & Complications
Complications
Severe neurodevelopmental impairment with profound intellectual disability
Recurrent seizures that may be difficult to control
Feeding and swallowing difficulties leading to failure to thrive
Respiratory complications from central apnea or aspiration pneumonia
Orthopedic deformities such as scoliosis and joint contractures
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Congenital Zika Syndrome (Zika Virus) versus Cytomegalovirus (CMV) Congenital Infection
Congenital Zika Syndrome (Zika Virus) | Cytomegalovirus (CMV) Congenital Infection |
|---|---|
Severe brain-volume loss and cortical-subcortical junction calcifications are characteristic | Periventricular calcifications are classic, but distributions overlap and neither pattern is diagnostic alone |
Maternal Zika virus infection during pregnancy | Maternal primary infection, reinfection or reactivation can lead to congenital CMV |
Infant serum/urine Zika NAAT, with IgM and selected confirmatory testing; maternal positivity alone does not establish infant infection | Urine CMV PCR within 21 days of birth; confirm a positive saliva screen with urine to establish congenital infection |
Congenital Zika Syndrome (Zika Virus) versus Toxoplasmosis Congenital Infection
Congenital Zika Syndrome (Zika Virus) | Toxoplasmosis Congenital Infection |
|---|---|
Often gray-white junction calcifications, cortical thinning and microcephaly | Classic combination: diffuse intracranial calcifications, hydrocephalus and chorioretinitis; all need not be present |
Prenatal maternal infection after mosquito or sexual exposure | Ingestion of tissue cysts in undercooked meat or oocysts in contaminated food, water or soil; cat ownership is not required |
Infant serum/urine Zika NAAT, with IgM and selected confirmatory testing; maternal positivity alone does not establish infant infection | Specialist infant IgM/IgA/IgG assessment and selected PCR; negative neonatal IgM alone does not exclude congenital toxoplasmosis |
Congenital Zika Syndrome (Zika Virus) versus Congenital Rubella Syndrome
Congenital Zika Syndrome (Zika Virus) | Congenital Rubella Syndrome |
|---|---|
Microcephaly/cortical injury, gray-white junction calcifications, retinal lesions and contractures | Cataracts, congenital heart disease (especially PDA/pulmonary artery stenosis) and sensorineural hearing loss |
Maternal Zika virus infection during pregnancy | Maternal rubella infection during first trimester |
Infant serum/urine Zika NAAT, with IgM and selected confirmatory testing; maternal positivity alone does not establish infant infection | Infant rubella IgM plus molecular testing, usually respiratory/throat and urine specimens; interpret with timing and epidemiology |
Congenital Zika Syndrome (Zika Virus) versus Fetal Alcohol Syndrome
Congenital Zika Syndrome (Zika Virus) | Fetal Alcohol Syndrome |
|---|---|
Brain growth/structural abnormalities with characteristic cortical-subcortical calcifications | Microcephaly and other structural or functional CNS abnormalities; intracranial calcifications are not a defining feature |
Maternal Zika virus infection during pregnancy | Maternal alcohol use during pregnancy |
Prenatal infectious injury with variable later neurologic/developmental manifestations | Prenatal alcohol-related developmental injury, with lifelong effects that may become clearer as demands increase; facial/growth findings help identify FAS |
Congenital Zika Syndrome (Zika Virus) versus Neonatal Herpes Simplex Virus (HSV) Infection
Congenital Zika Syndrome (Zika Virus) | Neonatal Herpes Simplex Virus (HSV) Infection |
|---|---|
Prenatal cortical malformation/volume loss and often gray-white junction calcifications | Neonatal HSV encephalitis can produce multifocal or diffuse injury; the classic adult temporal-lobe pattern is not required |
Maternal Zika infection in any trimester, with greater birth-defect risk early in gestation | Most neonatal HSV is acquired around delivery; new maternal genital infection near delivery is high risk, but an absent maternal history does not exclude it |
Infant serum/urine Zika NAAT, with IgM and selected confirmatory testing; maternal positivity alone does not establish infant infection | CSF HSV PCR for CNS disease, with lesion/mucosal and blood testing as indicated; an early negative CSF PCR may require repeat testing if suspicion remains high |